Cas No.: | 1577222-14-0 |
Chemical Name: | Diroximel fumarate |
Synonyms: | 2-(2,5-二氧代吡咯烷-1-基)乙基甲基富马酸酯;Diroximel fumarate;2-(2,5-Dioxopyrrolidin-1-yl)ethyl methyl fumarate;BIIB098;ALKS8700;K0N0Z40J3W;ALKS 8700;4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate;Diroximel Fumarete;Vumerity;diroximel-fumarate;Vumerity (TN);Diroximel fumarate [INN];Diroximel fumarate (USAN/INN);Diroximel fumarate [USAN:INN];GTPL10525;RDC5108;BCP20867 |
SMILES: | O(C(/C(/[H])=C(\[H])/C(=O)OC([H])([H])[H])=O)C([H])([H])C([H])([H])N1C(C([H])([H])C([H])([H])C1=O)=O |
Formula: | C11H13NO6 |
M.Wt: | 255.2240 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Diroximel fumarate (DRF) is a prodrug of monomethyl fumarate in a controlled-release formulation that rapidly and efficiently converts to MMF in the body[1]. |
References: | [1]. Angela Wehr, et al. Relative Bioavailability of Monomethyl Fumarate after Administration of ALKS 8700 and Dimethyl Fumarate in Healthy Subjects (P1.403). Neurology. Apr 2018. |